NORWALK, Conn., Sept. 17, 2007 (PRIME NEWSWIRE) -- The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a multi-center Phase I/II clinical program to explore the combination of TORISEL(tm) (temsirolimus), a novel mTOR inhibitor, and VELCADE(r) (bortezomib) for Injection, a proteasome inhibitor, for the treatment of relapsed or refractory multiple myeloma. Under the lead of Irene M. Ghobrial, M.D., of the Dana-Farber Cancer Institute, the study will also be conducted at two other MMRC Member Institutions, University of Michigan and Washington University.
